BioSpace News Archive

Eight iconic buildings in New York City, including the world-renowned Empire State Building, will light up blue on Wednesday, December 11 to commemorate the 36th annual Empire Ball and to shine a spotlight on the need for a diabetes cure.

ICON plc, (NASDAQ: ICLR) a leading global provider of drug and medical device development and commercialisation services, has won Best Contract Research Organisation – Full-Service Providers at the 2019 Scrip Awards, which took place in London on 4 December.

Nephron Pharmaceuticals Corporation today announced a new partnership with National Medical Products Inc. – developer of the J-Tip Needle Free Injector – that provides patients with an easy-to-use and virtually pain-free delivery of anesthetic medications prior to medical procedures.

RB and Evolve BioSystems announce a partnership in the sale of Evivo®, Evolve BioSystems’ infant probiotic.

Children’s Hospital of Philadelphia is proud to announce a partnership with The Enterprise Center, in conjunction with Philadelphia Housing Development Corporation, to build the number of licensed contractors in Philadelphia and expand CHOP’s Community Asthma Prevention Program Plus Home Repairs initiative.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening Microarray confirming feasibility of the MosaiQ system to address the needs of the Company’s donor center customers for molecular testing.

BIOASIS TECHNOLOGIES INC. is pleased to announce that all resolutions were passed by the requisite majority at its annual general meeting held earlier today in Toronto, Ontario.

Johnson & Johnson announced that Hubert Joly, Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger, Former EY Global Chairman and CEO, have been appointed to its Board of Directors..

GC4419 90 mg produced clinically meaningful reduction of severe oral mucositis duration, incidence and severity in Phase 2b clinical trial

U.S. – Based Ownership of Underlying Assets, IP and Key Personnel Focused on Greater Care Access for Core Patients, Including U.S. Military